Modification of Cardiovascular Risk Factors during Antihypertensive Treatment: A Multicentre Trial with Quinapril

Abstract

A large multicentre study involving 6003 [3044 males, 2959 females; mean (± SD) age 59 ± 11 years] mild-to-severe hypertensive patients was carried out to evaluate the effects of the angiotension converting enzyme inhibitor quinapril on blood pressure and on metabolic cardiovascular risk factors during 3 − 6 months' treatment (mean follow-up 90.4 days). The study population included 551 elderly [mean (± SD) age 71.9 ± 9.3 years] patients, 1314 subjects with diabetes mellitus and 154 non-diabetic patients with hyperlipaemia; 4% of patients were lost to follow-up. Diastolic blood pressure decreased from 102 to 87 mmHg (intent-to-treat analysis) and 62% of patients were normalized (diastolic blood pressure below 90 mmHg) at the last evaluable visit. Overall, serum lipids were favourably affected during quinapril treatment; when corrected for changes in body weight, a significant improvement in total, low- and high-density lipoprotein cholesterol, and triglycerides was detected. Quinapril treatment in elderly patients was efficacious and well tolerated, and quinapril appears to be an effective antihypertensive drug devoid of untoward effects on metabolic risk factors for cardiovascular disease.

Keywords

QUINAPRIL ANGIOTENSIN CONVERTING ENZYME INHIBITOR HYPERTENSIVES CARDIOVASCULAR RISK FACTORS HYPERTENSION

Get full access to this article

View all access options for this article.

References

Sytkowski

, Kannel

, D'Agostino

: Changes in risk factors and the decline in mortality from cardiovascular disease. N Engl J Med 1990; 322: 1635–1641.

Williams

: Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517–1525.

Salvetti

: Newer ACE inhibitors: a look at the future. Drugs 1990; 40: 800–823.

Wadworth

, Broden

: Quinapril: a review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs 1991; 41: 378–399.

Reaven

: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.

Ferrarrini

, Buzzigoli

, Bonadonna

: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–357.

Reaven

, Twersky

, Chang

: Abnormalities of carbohydrate and lipid metabolism in Dahl rats. Hypertension 1991; 18: 630–635.

Fournier

, Gadia

, Kubrusly

: Blood pressure, insulin and glycemia in non-diabetic subjects. Am J Med 1986; 83: 861–864.

Fuh

MM-T

, Shieh

S-M

, Wu

D-A

: Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med 1987; 147: 1035–1038.

10.

Ferrannini

: Metabolic abnormalities of hypertension: a lesson in complexity. Hypertension 1991; 18: 636–639.

11.

Pollare

, Lithell

, Berne

: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–873.

12.

Paolisso

, Gambardella

, Verza

: Quinapril reduces blood pressure and improves metabolic control in elderly hypertensive diabetic patients. Diabetes Metab 1990; 16: 264–265.

13.

Modan

, Halkin

, Almong

: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809–817.

14.

Ferrannini

, Haffner

, Stern

: Essential hypertension: an insulin-resistance state. J Cardiovasc Pharmacol 1990; 15 (suppl 5): S18–S25.

15.

Monolio

, Savage

, Burke

: Association of fasting insulin with blood pressure and lipids in young adults: the CARDIA study. Atherosclerosis 1990; 10: 430–436.

16.

Castelli

, Anderson

: A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med 1986; 80 (suppl 2A): 23–32.

17.

Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 to 129 mmHg. JAMA 1970; 213: 1143–1152.

18.

Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97–104.

19.

Helgeland

: Treatment of mild hypertension: a five-year controlled drug trial: the Oslo study. Am J Med 1908; 69: 725–732.

20.

Hypertension Detection and Follow-up Program Co-operative Group: Five-year findings of the Hypertension Detection and Follow-up Program. 1. Reduction in mortality of persons with high blood pressure including mild hypertension. JAMA 1979; 242: 2562–2571.

21.

Neaton

, Wentworth

: Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease: overall findings and differences by age for 316 099 white men. Arch Intern Med 1992; 152: 56–64.

22.

Lipid Research Clinics Program: The Lipid Research Clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–374.

23.

MacMahon

, Peto

, Cutler

: Blood pressure, stroke and coronary heart disease. I. Prolonged differences in blood pressure: prospective observation studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774.

24.

Multiple Risk Factor Intervention Trial: Research Group Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 248: 1465–1477.